Insomnia – Epidemiology – Emerging Markets

Clarivate Epidemiology’s coverage of insomnia comprises epidemiological estimates of key patient populations in the emerging pharmaceutical markets (Brazil, China, India, Mexico, Russia, South Korea, and Turkey). We report the prevalence of insomnia for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 10 years for the emerging pharmaceutical markets are covered in this report.

Clarivate Epidemiology’s insomnia forecast will answer the following question:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of insomnia over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following insomnia subpopulations:

  • Total prevalent cases of DSM-IV Insomnia by anxiety and mood disorders comorbidity status.
  • Total prevalent cases of DSM-IV Insomnia by obstructive sleep apnea comorbidity status.
  • Total prevalent cases of DSM-V Insomnia by anxiety and mood disorders comorbidity status.
  • Total prevalent cases of DSM-V Insomnia by obstructive sleep apnea comorbidity status.

Note: Coverage may vary by country.